- In July 2025, Atai Life Sciences and Beckley Psytech announced promising results from a Phase 2 trial of mebufotenin benzoate nasal spray for treatment-resistant depression. The one-time dose delivered clinically meaningful symptom relief within a day and lasted up to eight weeks, while most patients were ready for discharge just 90 minutes post-treatment—a major advance toward more accessible and cost-effective intranasal therapies
- In August 2023, Johnson & Johnson announced that the U.S. FDA approved Spravato (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). This expanded indication reflects Spravato’s clinically proven effectiveness in reducing depressive symptoms without the need for combination oral antidepressants, marking a major milestone in the evolution of intranasal therapies for mental health
